Hypera S.A. (BVMF:HYPE3)

Market Cap	15.90B +7.5%
Revenue (ttm)	8.82B +32.4%
Net Income	1.75B +136.2%
EPS	2.66 +127.9%
Shares Out	703.99M
PE Ratio	8.52
Forward PE	7.51
Dividend	1.17 (5.21%)
Ex-Dividend Date	Jun 29, 2026

Volume	1,211,100
Open	22.45
Previous Close	22.59
Day's Range	22.33 - 22.99
52-Week Range	19.88 - 27.79
Beta	0.11
Analysts	Strong Buy
Price Target	29.20 (+27.34%)
Earnings Date	Oct 27, 2026

About Hypera

Hypera S.A. operates as a pharmaceutical company in Brazil. The company provides sweeteners products under the Adocyl, finn, and Zero-cal brands; analgesics and anti-inflammatories products under the Doril, Atroveran, Calminex, Alivium, Buscopan, Buscofem, geloll, Torsilax, Neosaldina, and naprohax brands; cold and flu remedies and decongestants products under BENEGRIO, Rinosoro, Blu, Neosoro, Coristina, APRACUR, and Fluviral brands. It offers antihistamines products under Alektos, Histamin, Polaramine, PredSim, and Desrinite brands; antiseptic...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1999
• Employees: 10,564
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: HYPE3

Financial Performance

In 2025, Hypera's revenue was 7.70 billion, an increase of 3.45% compared to the previous year's 7.44 billion. Earnings were 1.20 billion, a decrease of -10.86%.

Analyst Summary

According to 15 analysts, the average rating for HYPE3 stock is "Strong Buy." The 12-month stock price target is R$29.20, which is an increase of 27.34% from the latest price.

Price Target

R$29.20

(27.34% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 10, 2026

Data Sources Report a data error